The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia.
The Task Force consisted of Endocrine Society-appointed experts, a methodologist,
and a medical writer.
This evidence-based guideline was developed using the Grading of Recommendations,
Assessment, Development, and Evaluation (GRADE) system to describe both the strength
of recommendations and the quality of evidence.
One group meeting, several conference calls, and e-mail communications enabled consensus.
Committees and members of The Endocrine Society, The European Society of Endocrinology,
and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines.
Practice guidelines are presented for diagnosis and treatment of patients with elevated
prolactin levels. These include evidence-based approaches to assessing the cause of
hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas
in nonpregnant and pregnant subjects. Indications and side effects of therapeutic
agents for treating prolactinomas are also presented.